Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2

M Catanzaro, F Fagiani, M Racchi, E Corsini… - Signal transduction and …, 2020 - nature.com
To date, no vaccines or effective drugs have been approved to prevent or treat COVID-19
and the current standard care relies on supportive treatments. Therefore, based on the fast …

COVID-19 outbreak: history, mechanism, transmission, structural studies and therapeutics

D Yesudhas, A Srivastava, MM Gromiha - Infection, 2021 - Springer
Purpose The coronavirus outbreak emerged as a severe pandemic, claiming more than 0.8
million lives across the world and raised a major global health concern. We survey the …

COVID-19 infection and rheumatoid arthritis: Faraway, so close!

EG Favalli, F Ingegnoli, O De Lucia, G Cincinelli… - Autoimmunity …, 2020 - Elsevier
The outbreak of the new coronavirus infections COVID-19 in December 2019 in China has
quickly become a global health emergency. Given the lack of specific anti-viral therapies, the …

COVID-19: drug targets and potential treatments

C Gil, T Ginex, I Maestro, V Nozal… - Journal of medicinal …, 2020 - ACS Publications
Currently, humans are immersed in a pandemic caused by the emerging severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), which threatens public health …

[HTML][HTML] Baricitinib as potential treatment for 2019-nCoV acute respiratory disease

P Richardson, I Griffin, C Tucker, D Smith… - Lancet (London …, 2020 - ncbi.nlm.nih.gov
Given the scale and rapid spread of the 2019 novel coronavirus (2019-nCoV) acute
respiratory disease, there is an immediate need for medicines that can help before a vaccine …

COVID-19: combining antiviral and anti-inflammatory treatments

J Stebbing, A Phelan, I Griffin, C Tucker… - The Lancet Infectious …, 2020 - thelancet.com
The Lancet, 3 we described how BenevolentAI's proprietary artificial intelligence (AI)-derived
knowledge graph, 4 queried by a suite of algorithms, enabled identification of a target and a …

Cytokine release syndrome in COVID-19: a major mechanism of morbidity and mortality

Y Que, C Hu, K Wan, P Hu, R Wang, J Luo… - International reviews …, 2022 - Taylor & Francis
Abstract The coronavirus disease 2019 (COVID-19) triggered by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) erupted in Hubei Province of China in December …

Baricitinib: a review of pharmacology, safety, and emerging clinical experience in COVID‐19

SCJ Jorgensen, CLY Tse, L Burry… - … : The Journal of …, 2020 - Wiley Online Library
A hyperinflammatory response to severe acute respiratory syndrome‐coronavirus 2 (SARS‐
CoV‐2) infection, reminiscent of cytokine release syndrome, has been implicated in the …

Protein–ligand binding with the coarse-grained Martini model

PCT Souza, S Thallmair, P Conflitti… - Nature …, 2020 - nature.com
The detailed understanding of the binding of small molecules to proteins is the key for the
development of novel drugs or to increase the acceptance of substrates by enzymes …

Repurposing of kinase inhibitors for treatment of COVID-19

E Weisberg, A Parent, PL Yang, M Sattler, Q Liu… - Pharmaceutical …, 2020 - Springer
The outbreak of COVID-19, the pandemic disease caused by the severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2), has spurred an intense search for treatments by the …